Intelligent
Living
Medicines
Adaptive Cell Therapies for Dynamic Disease
We are developing allogeneic (off-the-shelf) engineered cells designed to sense, compute, and respond to inflammatory disease cues in vivo. These living systems dynamically adapt inside the body to alter the progression of age-related and complex disorders—moving beyond static interventions toward continuous biological correction.
The Limits of Autologous Cell Therapy
Most cell therapies today are autologous and patient-specific, requiring bespoke manufacturing for every individual. This approach leads to prohibitive costs, long production timelines, and highly variable outcomes—severely limiting scalability, access, and consistency across patient populations.
A Standardized Platform for Personalized Biology
eCells™ are allogeneic, donor-independent, and standardized, enabling true off-the-shelf availability with significantly lower costs and predictable efficacy across patients. The platform integrates three core capabilities: disease-responsive sensing, functional cell-type differentiation, and immune evasion. We have de-risked the foundation by successfully engineering inflammatory sensing and directed differentiation—establishing a scalable base for intelligent living medicines.
A New Paradigm:
eCells™
Renue’s eCells™ are allogeneic, off-the-shelf engineered cells—donor-independent, standardized, and ready when patients need them. Designed as programmable biological systems, eCells™ overcome the limitations of autologous therapies by delivering:
- Immediate availability
- Significantly lower costs
- Consistent, predictable performance across patients
This shift unlocks scalability, accessibility, and repeatable clinical outcomes.eCells™ are engineered to function as living biological computers inside the body, integrating three core capabilities:
Disease-Responsive Sensing
Cells continuously monitor inflammatory and pathological cues in vivo, detecting disease states in real time
Functional Differentiation
Upon sensing disease signals, eCells™ dynamically differentiate into the appropriate functional cell types to deliver targeted therapeutic action.
Immune Evasion
Engineered mechanisms allow eCells™ to persist and function effectively within the host environment, avoiding premature immune rejection.
Together, these capabilities enable precision intervention that adapts over time, rather than one-time, static treatment.
Industries we work with
Construction
Safety protocols, equipment handling, and project management training.
Manufacturing
Lean manufacturing, machinery operation, quality control, and safety training.
Healthcare
Patient care, medical procedures, compliance, and healthcare technology training.
Energy & Utilities
Renewable energy systems, equipment maintenance, and environmental safety.
Logistics & Transportation
Supply chain management, vehicle safety, and regulatory compliance.
IT & Software Development
Coding languages, cybersecurity, software development methodologies, and IT compliance.
From Static Treatments to Living Medicine
Renue Life Sciences is redefining how complex and age-related diseases are treated—moving from one-time interventions to intelligent, living systems that adapt inside the body. With standardized, off-the-shelf eCells™, we are building a scalable foundation for durable, predictable, and accessible cell therapy.
Leadership
Presidential Fellow at MIT and an early contributor to CRISPR technology, he is also a fellow with Nobel Laureate Shinya Yamanaka, whose work on stem cells earned a Nobel Prize.
15+ years in R&D, Translational Sciences, and CMC with leadership across 7+ drug programs.
Expert in PK/PD, IND-enabling studies, biomarkers, regulatory compliance, and CGT/RNA therapeutics.
$2M+ in grants, 20+ publications (genomics, pain biology, CRISPR), and active advisor to startups and strategic partnerships.
Let’s Build the Future of Living Medicine
Whether you’re a researcher, partner, investor, or collaborator, we’d love to hear from you. Reach out to explore how Renue Life Sciences and eCells™ are advancing scalable, intelligent cell therapies for complex disease.
.png)